mTOR Inhibitor

mTOR Inhibitors (353):

Cat. No.	Product Name	Effect	Purity

HY-173367

Anticancer agent 271	Inhibitor
Anticancer agent 271 (compound 5C) has antiproliferative activity against lung (A549), colon (Caco-2) cancer cell lines, and human lung fibroblast (WI38) with an IC₅₀ value of 9.18 μM on A549 cells. Anticancer agent 271 downregulates PI3K and mTOR gene expression that can be used for cancer research.

HY-120406

PLS-123	Inhibitor
LPS-123 is a covalently irreversible BTK inhibitor with an IC₅₀ of < 5 nM. LPS-123 simultaneously inhibits the catalytic activity of BTK at Tyr551 and its self-activation at Tyr223. LPS-123 inhibits phosphorylation of the AKT/mTOR and MAPK signaling pathways, activation of PLCγ2, ERK1/2, p38, AKT, and mTOR, and blocks the production of CCL3 and CCL4 chemokines. LPS-123 exhibits significant anti-proliferative activity against various B-cell lymphoma cell lines and effectively induces apoptosis via a caspase-dependent pathway. LPS-123 also demonstrates significant antitumor activity in the OCI-Ly7 xenograft model. LPS-123 can be used for lymphoma research.

HY-N0112R

Dihydromyricetin (Standard)	Inhibitor
Dihydromyricetin (Standard) is the analytical standard of Dihydromyricetin. This product is intended for research and analytical applications. Dihydromyricetin is a potent inhibitor with an IC₅₀ of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting mTOR signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 22 μM.

HY-176435

mTOR inhibitor-28	Inhibitor
mTOR inhibitor-28 (SM-3) is a potent mTOR inhibitor. mTOR inhibitor-28 inhibits A549, H292, and H460 cells with IC₅₀s of 72.74, 67.66, and 43.24 μM, respectively.

HY-169407

AKT-IN-24	Inhibitor
KT-IN-24 (Compound M17) is a AKT allosteric inhibitor with anti-tumor activity. KT-IN-24 can target the AKT/mTOR and MEK/ERK signaling pathways and inhibit epithelial-mesenchymal transition, which has a synergistic suppressive effect on TNBC, promoting cell apoptosis while inhibiting proliferation and migration when used in combination with Trametinib (HY-10999).

HY-168893

K882	Inhibitor
K882 (Compound 4e) is a Src inhibitor, with K_D of 0.315 μM. K882 induces Apoptosis. K882 inhibits XIAP and Survivin. K882 inhibits the activation of PI3K/Akt/mTOR, Jak1/Stat3, Ras/MAPK signaling pathways. K882 shows anti-tumor activity against non-small cell lung cancer.

HY-146200

PI3K/mTOR Inhibitor-8	Inhibitor
PI3K/mTOR Inhibitor-8 (Compound 18b) is a PI3K and mTOR dual inhibitor with IC₅₀ values of 0.46 nM and 12 nM against PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-8 induces HCT-116 cells apoptosis and arrests cell cycle at the G1/S phase.

HY-151915

ATR-IN-20	Inhibitor
ATR-IN-20 is a potent ATR (ATM/ATR) inhibitor with an IC₅₀ of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC₅₀ of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects.

HY-178812

PI3Kα-IN-27	Inhibitor
PI3Kα-IN-27 (Compound 50b) is an orally active PI3K-α inhibitor, with an IC₅₀ of 40 nM. PI3Kα-IN-27 effectively inhibits PAK3, p110α, phospho-mTOR and phospho-ERK1/2. PI3Kα-IN-27 induces early Apoptosis. PI3Kα-IN-27 shows anticancer activity against pancreatic cancer, lung cancer, breast cancer.

HY-161856

Antifungal agent 106	Inhibitor
Antifungal agent 106 (Compound Z31) is a benzoic acid derivative and a potential fungicide against Monilinia fructicola. Antifungal agent 106 exhibits antifungal activity with an EC₅₀ value of 11.8 mg/L. It affects hyphal growth by disrupting cell membrane integrity, leading to increased membrane permeability and release of intracellular electrolytes. Antifungal agent 106 can be used in research related to brown rot of stone fruits.

HY-170405

YB-3–17	Inhibitor
YB-3-17 is a bifunctional molecule, that inhibits mTOR (IC₅₀=0.22 nM) or degrades G1 to S phase transition 1 gene (GSPT1, DC₅₀=5 nM) in a PROTAC mechanism. YB-3-17 exhibits antiproliferative activity in multi glioblastoma cell lines with IC₅₀ of nanomolare levels. YB-3-17 exhibits antitumor efficacy in mouse models. (Pink: ligand for target protein (HY-170407); Black: linker (HY-A0102); Blue: ligand for E3 ligase Cereblon (HY-14658))

HY-147913

PI3K/Akt/mTOR-IN-3	Inhibitor
PI3K/Akt/mTOR-IN-3 (compound 3d) is a potent PI3K/AKT/mTOR inhibitor. PI3K/Akt/mTOR-IN-3 displays the inhibitory activity in MCF-7, HeLa and HepG2 cells, with IC₅₀ values of 0.77, 1.23, and 4.57μM, respectively. PI3K/Akt/mTOR-IN-3 inhibits the migration of MCF-7 and HeLa cells at the concentration of 4 μM. PI3K/Akt/mTOR-IN-3 induces cell apoptosis and S phase arrest.

HY-175646

AGPAT4-IN-1	Inhibitor
AGPAT4-IN-1 (Compound CL26) is a covalent AGPAT4 inhibitor with an IC₅₀ of 795 nM. AGPAT4-IN-1 covalently binds to AGPAT4 at Cys²²⁸ and significantly inhibits acyltransferase activity, LPA-to-PA conversion and downstream mTOR/S6K pathways. AGPAT4-IN-1 sensitizes hepatocellular carcinoma (HCC) tumors to Sorafenib (HY-10201) and significantly induces apoptosis with a synergistic response. AGPAT4-IN-1 has antitumor activity and reduces tumorigenicity and stemness in HCC xenograft mouse models.

HY-169022

4-FPBUA	Inhibitor
4-FPBUA is a semisynthetic analog of usnic acid (HY-W015883) that can enhance cellular blood-brain barrier (BBB) function and increase the transport of Amyloid β (Aβ) across monolayer cells. 4-FPBUA is also an inhibitor of mTOR, capable of enhancing cellular Autophagy, thereby reversing BBB disruption in vivo and being utilized in research for Alzheimer's disease.

HY-154910

CC214-1	Inhibitor	98.49%
CC214-1 is a potentially efficacious mTOR inhibitor that induces autophagy ,with an IC₅₀ is 0.002 μM. CC214-1 proved to be useful as an in vitro tool compound for the exploration of mTOR kinase biology. CC214-1 can be used for Glioblastoma study.

HY-121726

3HOI-BA-01	Inhibitor
3HOI-BA-01 is amTORinhibitor.3HOI-BA-01reduces infarct size and inducedautophagyin a murine myocardial ischemia/reperfusion injury model.

HY-N0656AR

(+)-Usnic acid (Standard)	Inhibitor
(+)-Usnic acid (Standard) is the analytical standard of (+)-Usnic acid. This product is intended for research and analytical applications. (+)-Usnic acid is isolated from isolated from lichens, binds at the ATP-binding pocket of mTOR, and inhibits mTORC1/2 activity. (+)-Usnic acid inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer activity. (+)-Usnic acid possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium.

HY-15901A

LGB321 monohydrochloride	Inhibitor
LGB321 monohydrochloride is a potent, selective, orally active and ATP competitive inhibitor of all three PIM kinases. LGB321 monohydrochloride inhibits proliferation, mTOR-C1 signaling and phosphorylation of BAD in a number of cell lines derived from diverse hematologic malignancies. LGB321 monohydrochloride can be used for the research of hematologic malignancies.

HY-108959

D-87503	Inhibitor
D-87503 is a potent inhibitor of PI3k/Akt/mTOR, with the IC₅₀s of 62 nM and 0.76 μM, respectively for PI3k and Erk2. D-87503 effectively suppressed the target downstream substrates Akt and Rsk1 kinase of the PI3k/Akt/mTOR signaling pathway.

HY-N12124

Monascuspiloin	Inhibitor
Monascuspiloin (Monascinol) exhibits anti-androgenic activity with an IC₅₀ of 7 μM. Monascuspiloin inhibits viability of PC-3 and LNCaP with IC₅₀ of 45 and 47 μM. Monascuspiloin induces apoptosis in LNCaP through inhibition of Akt/mTOR signaling pathway, induces autophagy through activation AMPK signaling pathway and arrest cell cycle at G2/M phase in PC-3. Monascuspiloin exhibits antitumor efficacy in mice.

Name
Email *

	Sorry, but the email address you supplied was invalid.